Adimab, LLC has licensed its technology transfer program to Novo Nordisk and will receive upfront payments, annual licensing fees and royalties on commercialized products. Novo Nordisk has been granted a non-exclusive license to use Adimab’s antibody platform for the discovery and optimization of antibodies.
“We are pleased to have expanded our partnership with Novo Nordisk,” said Tillman Gerngross, chief executive officer and co-founder of Adimab. “This is the third platform transfer this year, and this transaction with Novo Nordisk further validates our view that leading pharma companies have a need for better antibody discovery and optimization tools. At this point in time, our platform is the leading technology for antibody discovery and optimization, but, we haven’t rested on our laurels; we have over 25 people working on improving and expanding the platform’s capabilities to make sure that we stay ahead of the field.”
“We are very pleased to have established a broad relationship with Adimab,” said Hanne Risager Romedahl, vice president of Novo Nordisk. “We feel confident that Adimab offers a comprehensive solution for our antibody discovery needs. In addition to using the platform as a rapid IgG discovery engine, we are particularly impressed with the ability to optimize antibodies with this broad protein engineering tool. This capability will nicely complement and enhance our existing antibody discovery technologies.”
Novo Nordisk Licenses Adimab Tech Transfer Program
Published September 27, 2013
blog comments powered by Disqus